Futureproofing supply chains in an evolving pharmaceutical industry
Pharmaceutical supply chains are some of the world’s most intricate. Recent developments have only heightened the challenges for companies on …
Pharmaceutical supply chains are some of the world’s most intricate. Recent developments have only heightened the challenges for companies on …
Onward Medical has raised $54m (€50m) via a bookbuild offering, with proceeds going towards ongoing clinical studies and an expected …
OKYO Pharma has initiated the Phase II trial of OK-101, a treatment for neuropathic corneal pain (NCP), by dosing the …
During IDWeek 2024 in Los Angeles, California, US, case studies highlighted the current methods for detecting and preventing nontuberculous mycobacteria …
Managing chronic myeloid leukemia (CML) can be challenging, especially when it comes to accurately tracking how well patients respond to …
AngioDynamics has teamed up with the University College London Hospital (UCLH) in the UK to launch a prospective registry study …
US-based device company Luna Diabetes has initiated a pivotal trial evaluating its automated closed-loop insulin technology, the Luna System, in …
Artificial intelligence (AI) is widely considered to be the technology that will offer the most benefits for clinical trials. In …
Artificial intelligence (AI) is widely considered to be the technology that will offer the most benefits for clinical trials. In …
The US National Institutes of Health (NIH) has launched a precision medicine trial that aims to match patients with myeloid …
Calluna Pharma has concluded the Phase I clinical study of its lead product, CAL101, for fibrotic and fibro-inflammatory indications. CAL101 is …
Repare Therapeutics has presented updated data from its Phase I MYTHIC clinical trial, which shows the benefits of an individualised …
A Phase III clinical trial is being launched in the UK to investigate Moderna’s norovirus vaccine mRNA-1403. This is the first …
Genelux has dosed the first subject in the Phase II VIRO-25 clinical trial in the US, designed to assess the …
On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 receptor (GLP-1R) agonist, …